Cargando…
Tocilizumab in severe COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Termedia Publishing House
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667418/ https://www.ncbi.nlm.nih.gov/pubmed/33224347 http://dx.doi.org/10.5114/aoms.2020.97411 |
| _version_ | 1783610309177507840 |
|---|---|
| author | Lucio Liberato, Nicola De Monte, Andrea Caravella, Giuseppe |
| author_facet | Lucio Liberato, Nicola De Monte, Andrea Caravella, Giuseppe |
| author_sort | Lucio Liberato, Nicola |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7667418 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Termedia Publishing House |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76674182020-11-20 Tocilizumab in severe COVID-19 Lucio Liberato, Nicola De Monte, Andrea Caravella, Giuseppe Arch Med Sci Letter to the Editor Termedia Publishing House 2020-07-16 /pmc/articles/PMC7667418/ /pubmed/33224347 http://dx.doi.org/10.5114/aoms.2020.97411 Text en Copyright: © 2020 Termedia & Banach http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
| spellingShingle | Letter to the Editor Lucio Liberato, Nicola De Monte, Andrea Caravella, Giuseppe Tocilizumab in severe COVID-19 |
| title | Tocilizumab in severe COVID-19 |
| title_full | Tocilizumab in severe COVID-19 |
| title_fullStr | Tocilizumab in severe COVID-19 |
| title_full_unstemmed | Tocilizumab in severe COVID-19 |
| title_short | Tocilizumab in severe COVID-19 |
| title_sort | tocilizumab in severe covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667418/ https://www.ncbi.nlm.nih.gov/pubmed/33224347 http://dx.doi.org/10.5114/aoms.2020.97411 |
| work_keys_str_mv | AT lucioliberatonicola tocilizumabinseverecovid19 AT demonteandrea tocilizumabinseverecovid19 AT caravellagiuseppe tocilizumabinseverecovid19 |